Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007142542 - CATIONIC MILK PROTEINS FOR TREATING MASTITIS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

WHAT I/WE CLAIM IS:

1. A treatment composition for treating or preventing bovine mastitis,

the treatment composition characterised in that it includes at least two components which have an isoelectric point of or above substantially 6.8 and is extracted from milk, or a milk derived substance.

2. A treatment composition as claimed in claim 1 wherein the treatment composition is a cationic fraction which includes at least lactoferrin, lactoperoxidase and angiogenin.

3. A treatment composition as, claimed in either claim 1 or 2, wherein the composition also includes CLP-1.

4. A treatment composition as claimed in any one of claims 1 to 3, wherein the composition also includes a mixture of cationic peptides.

5. A treatment composition as claimed in any one of claims 1 to 4, wherein the composition also includes at least one of the following: N-acetyi glucosaminidase, serum amyloid A, β Defensin or iysozyme.

6. A treatment composition as claimed in any one of claims 1 to 5, wherein the composition also includes lactoferricin.

7. A treatment composition as claimed in any one of claims 1 to 6, wherein the composition also includes at least one immunoglobulin.

8. A treatment composition as claimed in any one of claims 1 to 7, wherein the composition also includes growth factors.

9. A treatment composition as claimed in any one of claims 1 to 8, wherein the composition is extracted from whole milk.

10. A treatment composition as claimed in any one of claims 1 to 9, wherein the composition is extracted "on-farm", during or directly after the milking process.

11. A treatment composition as claimed in any one of claims 1 to 10, wherein the composition is extracted from milk or milk-derived substance from a genetically modified animal.

12. A treatment composition as claimed in any one of claims 1 to 11 , wherein the composition is used to form part of a final treatment composition.

13. A final treatment composition as claimed in claim 12 which also includes one or more of the following: antibiotics, analgesics, carriers, buffers, preservatives, excipients, time release, hardening or other pharmaceutically acceptable components.

14. A final treatment composition as claimed in either claim 12 or claim 13 which is configured to be used as one of the following: teat seals, teat sprays, teat wipes, udder/teat washes, milking cluster backflush solutions or intramammary formulations.

15. A final treatment composition as claimed in any one of claims 12 to 14 wherein the composition is provided in a concentration range of 2 - 20% (w/w).

16. A method of treating or preventing bovine mastitis using a treatment compound as claimed in any one of claims 1 to 15, the method characterised by the step of applying the treatment compound onto or into at least one bovine teat.

17. A method of treating or preventing bovine mastitis as claimed in claim 16 wherein the composition is extracted from the same species of animal that is intended to be treated with the composition.

18. A treatment formulation which includes,

a treatment composition extracted from milk, or a milk derived substance, wherein the fraction contains at least two components with an isoelectric point of or greater than substantially 6.8, and

a cell lysing substance.

19. An antimicrobial treatment formulation which includes,

a treatment composition extracted from milk, or a milk derived substance, wherein the fraction contains at least two components with an isoelectric point of or greater than substantially 6.8, and

a cell lysing substance.

20. A treatment formulation as claimed in either claim 18 or ciaim 19 wherein the formulation also includes one or more of the following:

1. a peroxidase substrate, and/or

2. hydrogen peroxide or a source of hydrogen peroxide.

21. A treatment composition as claimed in any one of claims 18 to 20 wherein the cell iysing substance is a monoglyceride.

22. A treatment formulation as claimed in either claim 20 or 21 wherein the peroxidase substrate is sodium thiocyanate.

23. A treatment formulation as claimed in any one of claims 20 to 22 wherein the source of hydrogen peroxide used is ascorbate or ascorbic acid.

24. A treatment formulation as claimed in any one of claims 18 to 23 wherein the treatment composition is a cationic fraction which includes any components of milk which have an isoelectric point of or above substantially 6.8.

25. A treatment formulation as claimed in any one of claims 18 to 24 wherein the composition also includes CLP-1.

26. A treatment formulation as claimed in any one of claims 18 to 25, wherein the composition also includes a mixture of cationic peptides.

27. A treatment formulation as claimed in any one of claims 18 to 26, wherein the composition also includes at least one of the following: N-acetyl glucosaminidase, serum amyloid A, β Defensin or lysozyme.

28. A treatment formulation as claimed in any one of claims 18 to 27, wherein the composition also includes iactoferricin.

29. A treatment formulation as claimed in any one of claims 18 to 28, wherein the composition also includes at least one immunoglobulin.

30. A treatment formulation as claimed in any one of claims 18 to 29, wherein the composition also includes growth factors.

31. A treatment formulation as claimed in any one of claims 18 to 30, wherein the composition is extracted from whole milk.

32. A treatment formuiation as claimed in any one of claims 18 to 31 , wherein the composition is extracted "on-farm", during or directly after the milking process.

33. A treatment formulation as claimed in any one of claims 18 to 32, wherein the composition is extracted from a genetically modified animal.

34. A treatment formulation as claimed in any one of claims 18 to 33, wherein the composition is used to form part of a final treatment composition.

35. A final treatment composition as claimed in claim 34 which also includes one or more of the following: antibiotics, analgesics, carriers, buffers, preservatives, excipients, time release, hardening or any other pharmaceutically acceptable component.

36. A final treatment composition as claimed in either claim 34 or claim 35 which is configured to be used as one of the following: teat seals, teat sprays, teat wipes, udder/teat washes, milking cluster backflush solutions or intramammary formulations.

37. A finaf treatment composition as claimed in claim 34 or claim 35 wherein the final composition is configured to be used as a general antibiotic.

38. A final treatment composition as claimed in any one of claims 34 to 37 wherein the composition is provided in a concentration range of 2 - 20% (w/w)

39. A method of extracting a treatment compound from milk, including the steps of:

a) passing milk through an extraction material, and

b) eluting a fraction of the bound milk components

wherein parameters of the extraction process provides a cationic fraction which includes at least two components with an isoelectric point of or above substantially 6.8,

the method characterised in that the step b) is conducted once.

40. A method as claimed in claim 39 wherein the extraction material is a cation exchange material.

41. A method as claimed in claim 40 wherein the cation exchange material has a mean particle size in excess of 100 μm.

42. A method as claimed in any one of claims 39 to 41 wherein the fraction is eluted with a salt solution.

43. A method as claimed in any one of claims 39 to 42 wherein the fraction is eluted in a salt solution between substantially 10 mS and 100 mS conductivity

44. A method as claimed in any one of claims 39 to 43 wherein the method also includes a desalting step.

45. A method as claimed in any one of claims 39 to 44 wherein the method also includes a concentration step.

46. A method as claimed in claim 45 wherein the fraction is concentrated to approximately 20% solids.

47. A treatment composition produced by the method as claimed in any one of claims 39 to 46 for the treatment and/or prevention of bovine mastitis.

48. A method of treating bovine mastitis using a treatment compound formed by the method as claimed in any one of claims 39 to 47, the method characterised by the step of applying the treatment compound onto or into at least one bovine teat.

49. A treatment composition substantially as herein described with reference to the accompanying description and examples.

50. A treatment formulation substantially as herein described with reference to the accompanying description and examples.

51. An antimicrobial treatment formulation substantially as herein described with reference to the accompanying description and examples.

52. A method of extracting a treatment compound from milk substantially as herein described with reference to the accompanying description and examples.